AUG 21, 2020 1:42 PM PDT

Cancer Feels the STING

WRITTEN BY: Tara Fernandez

Researchers have discovered a protein that can amplify immune reactions against tumors. The stimulator of interferon genes, or STING for short, sends out signals to attract immune cells particularly during viral infections and the once cancerous cells are detected. STING has piqued the attention of oncology drug developers, particularly those who are hoping to harness its potent antitumor effects for new therapeutics.

Early work into creating STING-based treatments hit a roadblock due to the instability of STING activators — levels of these activators naturally taper off over time and do not last long in circulation.

A new study published in Science describes efforts by Scripps Research scientists who screened an array of small molecules with different structural conformations in search of those that activate STING. They discovered a single molecule which once optimized, was found to evoke a robust immune response in mouse models of metastatic melanoma, and curtailing the spread of the cancer.

Luke Lairson, co-senior author of the study said, “A systemic STING-activating molecule could have considerable utility, and not only as a therapeutic for cancer and infectious disease but also as a probe for studying STING-dependent antitumor immunity and a host of other STING-related biological processes.” 

The synthetic STING activator termed SR-717 mimics naturally occurring activators and has exciting potential as a future oncology drug. Once administered to mice with a particularly aggressive form of melanoma, SR-717 slowed tumor growth to a halt, blocked metastasis, and flagged immune cells such as CD8-positive and natural killer cells, mounting a full-blown cancer-killing response, all with no evidence of any unwanted side effects.

 


Sources: Science, Scripps Research.

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
APR 16, 2021
Microbiology
A New Kind of COVID-19 Vaccine
APR 16, 2021
A New Kind of COVID-19 Vaccine
The current COVID-19 vaccines by Pfizer/BioNTech and Modern are based on messenger RNA, which cells use to make proteins ...
APR 21, 2021
Immunology
Human T Cells Can't Recognize COVID Mutants
APR 21, 2021
Human T Cells Can't Recognize COVID Mutants
Genetic variants of the SARS-CoV-2 virus have emerged and tightened their grip on global communities as the pandemic rag ...
MAY 24, 2021
Cell & Molecular Biology
Animal Trial of Asthma Vaccine Has Positive Results
MAY 24, 2021
Animal Trial of Asthma Vaccine Has Positive Results
Asthma is thought to affect 340 million people. A type of asthma that happens when allergens like dust mites are inhaled ...
JUN 16, 2021
Immunology
Researchers Identify a Novel COVID Therapeutic Target and Mortality Predictor
JUN 16, 2021
Researchers Identify a Novel COVID Therapeutic Target and Mortality Predictor
Researchers at King’s College London have discovered a new antiviral target to combat COVID-19: the galectin-3-bin ...
JUL 05, 2021
Health & Medicine
No Rise in Acid-Related Diseases After Reduction of PPI Use
JUL 05, 2021
No Rise in Acid-Related Diseases After Reduction of PPI Use
In a study including several million veterans as participants, researchers at the University of Michigan found that an i ...
JUL 29, 2021
Drug Discovery & Development
What is Ivermectin and Can it Treat COVID?
JUL 29, 2021
What is Ivermectin and Can it Treat COVID?
Lab tests in 2020 found that the widely available drug ivermectin had a weak effect on the SARS-CoV-2 virus and that unf ...
Loading Comments...